Overview

A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This open-label, single-dose, parallel-group study will investigate the pharmacokinetics and safety of RO4917838 in healthy and renal impaired subjects. Subjects will receive a single dose of RO4917838.
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche